The extent and depth of the ongoing opioid crisis are well known and many interventions are under way in the United States and other countries to alleviate its devastating impact on individuals and the society. To address specific challenges of pain and opioid management (POM) in older and vulnerable adults, the investigators will design and implement a multi-faceted, person-centered, and scalable opioid use disorder (OUD) management program in Oklahoma primary care practices. The investigators expect that the rigorously designed and evidence-based program will establish and disseminate innovative solutions for pain and opioid management in high-risk, older and vulnerable populations living with chronic pain. The proposed initiative will help primary care practices optimize pain management approaches in older adults through an integrated and trans-disciplinary application of innovations in multi-modal pain management, pain mechanism-based pharmacotherapy, patient goal-oriented care, implementation science, evidence-based quality improvement methodology, and community-engaged design.
The project's specific aims are: 1. Building upon existing guidelines and tools that the investigators' collaborative has developed and implemented for pain and opioid management (POM), refine and tailor care processes, implementation support strategies, and shared decision support resources to the specific needs of older adults in primary care settings, using a systematic approach, including: 1. Conduct a rapid, iterative process, through which a diverse healthcare professional expert panel adapts and enhances existing POM approaches and tools to older adult patients (POMOA); 2. Implement a subsequent formative process, through which a patient and caregiver community advisory board ensures that the tailored POM approach and resources are acceptable, usable, context-sensitive and value-added for older adults and their caregivers; and 3. Assemble tailored resources to create a POMOA Toolkit from which primary care practices can select sets of resources based on their specific needs, guided by academic detailers and practice facilitators. 2. Over a 2-year period, help a minimum of 36 Oklahoma primary care practices implement a person-centered, goal-oriented, and community-linked approach to pain management, tailored to older adults. The implementation approach will include the following: 1. Using benchmarking and performance feedback, academic detailing, practice facilitation, and technology support, help practices integrate the tailored POMOA approach and resources into their workflows, focusing on improving patient functioning, self-efficacy, and the optimization of pain management; and 2. Through ongoing observation and analysis, identify facilitators and barriers to program implementation to accelerate convergence on effective and replicable methods. 3. Conduct a multi-dimensional and comprehensive evaluation of the impact of the RISE-OK program, including the measurement of the following outcomes: 1. Patient-Centered Outcomes: Patient health-related quality of life and functioning (PROMIS-29), self- efficacy for pain management using a modified Arthritis Self-Efficacy scale (ASES), pain interference (Pain-Enjoyment-General Activity), and functional goal attainment (Goal Attainment Scaling); 2. Care Quality Outcomes: Patient utilization of opioid medications (morphine milligram equivalents) and alternative therapies in older adults, change in prescribing patterns, and diversification of pharmacological and non-pharmacological pain therapies; 3. Care Process Outcomes: Impact of the program on practice-level care process outcomes (chronic opioid therapy registry use; systematic chronic opioid therapy visits; pain impact/interference measurement, pain management and risk/benefit conversations; naloxone prescription; tapering practices; patient/caregiver education; shared decision-making; referrals/community service linkages; medication assisted therapy utilization); and 4. Qualitative Outcomes: Healthcare professional, health system leadership, patient, and caregiver perceptions of the utility, effectiveness and generalizability of the RISE-OK program, explored via semi-structured interviews, exit surveys, and in-depth program implementation process observations. 4. Disseminate innovative approaches and products developed by the RISE-OK project in several ways: 1. Community-based dissemination (community-based and professional health organizations); 2. Academic dissemination (presentations, workshops, papers, Agency for Healthcare Research and Quality's communication professionals); Web-based and social networking-based dissemination (e.g., Research-to-Practice Exchange).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
1,035
The study will employ a research and implementation design that attempts to balance scientific rigor, research good practices, primary care implementation preferences and numerous limitations related to the study context. A waitlist-controlled, staggered implementation study will be conducted with three groups of 15 practices introduced to the intervention in 3-month intervals, each baseline overlapping with interim measurements of care quality and process outcomes in concurrent groups in every 3 months, followed by a final data collection at the end of the intervention in months 16 and 17, including baseline measures plus semi-structured interviews. The groups and their sequence will not be randomized, but practice characteristics will be used to distribute them among the three groups based on location, type, size and patient mix to maximize the balance of practices among the groups.
Oklahoma Clinical and Translational Science Institute
Oklahoma City, Oklahoma, United States
RECRUITINGHealth-Related Quality of Life and Functioning: Physical Health Summary Score
Change in Patient-Reported Outcomes Measurement Information System Survey (PROMIS-29) Physical Health Summary Score
Time frame: Baseline to 17 months
Health-Related Quality of Life and Functioning: Mental Health Summary Score
Change in Patient-Reported Outcomes Measurement Information System Survey (PROMIS-29) Mental Health Summary Score
Time frame: Baseline to 17 months
Morphine Milligram Equivalent (MME)
Change in mean opioid Morphine Milligram Equivalent (MMEs) at the practice level
Time frame: Baseline to 17 months
Self-Efficacy
Arthritis Self-Efficacy Scale (ASES) Score. The Arthritis Self-Efficacy Scale has 20 items in 3 subscales: self-efficacy for managing pain (PSE), 5 items; self-efficacy for physical function (FSE), 9 items; and self-efficacy for controlling other systems (OSE), 6 items. Items are rated on a 1 (very uncertain) to 10 (very certain) rating scale. Higher scores indicate greater confidence or self-efficacy.
Time frame: Baseline
Self-Efficacy
Arthritis Self-Efficacy Scale (ASES) Score. The Arthritis Self-Efficacy Scale has 20 items in 3 subscales: self-efficacy for managing pain (PSE), 5 items; self-efficacy for physical function (FSE), 9 items; and self-efficacy for controlling other systems (OSE), 6 items. Items are rated on a 1 (very uncertain) to 10 (very certain) rating scale. Higher scores indicate greater confidence or self-efficacy.
Time frame: 17 months
Pain-Function Interference
3-item Pain-Enjoyment-General Activity (PEG) score
Time frame: Baseline
Pain-Function Interference
3-item Pain-Enjoyment-General Activity (PEG) score
Time frame: Month 5
Pain-Function Interference
3-item Pain-Enjoyment-General Activity (PEG) score
Time frame: Month 8
Pain-Function Interference
3-item Pain-Enjoyment-General Activity (PEG) score
Time frame: Month 12
Pain-Function Interference
3-item Pain-Enjoyment-General Activity (PEG) score
Time frame: Month 17
Pain-Related Goal Attainment
Summary of 3-point Pain-Related Goal Attainment Scaling. Patients will rate their Pain-Related Goal Attainment using a 3-category response scale (somewhat less than expected (-1), expected goal achievement (0), and somewhat better than expected (+1).
Time frame: Baseline
Pain-Related Goal Attainment
Summary of 3-point Pain-Related Goal Attainment Scaling. Patients will rate their Pain-Related Goal Attainment using a 3-category response scale (somewhat less than expected (-1), expected goal achievement (0), and somewhat better than expected (+1).
Time frame: Month 17
Polypharmacy Risk
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Time frame: Baseline
Polypharmacy Risk
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Time frame: Month 5
Polypharmacy Risk
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Time frame: Month 8
Polypharmacy Risk
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Time frame: Month 12
Polypharmacy Risk
% of Patients also on psychotropics, sedative-hypnotics, muscle relaxants, or cannabionoids
Time frame: Month 17
Diversification of Pain Therapy
Number (and Type) of pharmacological and non-pharmacological treatment types
Time frame: Baseline
Diversification of Pain Therapy
Number (and Type) of pharmacological and non-pharmacological treatment types
Time frame: Month 5
Diversification of Pain Therapy
Number (and Type) of pharmacological and non-pharmacological treatment types
Time frame: Month 8
Diversification of Pain Therapy
Number (and Type) of pharmacological and non-pharmacological treatment types
Time frame: Month 12
Diversification of Pain Therapy
Number (and Type) of pharmacological and non-pharmacological treatment types
Time frame: Month 17
Chronic Opioid Therapy Statistics: Eligible Patients
Number of patients 60+ years of age on chronic opioids
Time frame: Baseline
Chronic Opioid Therapy Statistics: Eligible Patients
Number of patients 60+ years of age on chronic opioids
Time frame: Month 17
Chronic Opioid Therapy Statistics: Visit Addressing Pain Management
% of patients on chronic opioids that were seen at a visit addressing pain management in the 6 months prior to Baseline.
Time frame: Baseline
Chronic Opioid Therapy Statistics: Visit Addressing Pain Management
% of patients on chronic opioids that were seen at a visit addressing pain management in the 6 months prior to Month 17 of the study.
Time frame: Month 17
Chronic Opioid Therapy Statistics: Chronic Pain Diagnosis
% of patients on chronic opioids with a chronic pain diagnosis
Time frame: Baseline
Chronic Opioid Therapy Statistics: Chronic Pain Diagnosis
% of patients on chronic opioids with a chronic pain diagnosis
Time frame: Month 17
Chronic Opioid Therapy Statistics: High Risk Patients
% of patients on chronic opioids with MME\>50 and benzo
Time frame: Baseline
Chronic Opioid Therapy Statistics: High Risk Patients
% of patients on chronic opioids with MME\>50 and benzo
Time frame: Month 17
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.